Androgen deprivation therapy and excess mortality in men with prostate cancer during the initial phase of the COVID-19 pandemic.
<h4>Background</h4>Men have a higher risk of death from COVID-19 than women and androgens facilitate entrance of the SARS-CoV-2 virus into respiratory epithelial cells. Thus, androgen deprivation therapy may reduce infection rates and improve outcomes for COVID-19. In the spring of 2020,...
Guardado en:
Autores principales: | Rolf Gedeborg, Johan Styrke, Stacy Loeb, Hans Garmo, Pär Stattin |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/a67848ce438c4c64b9b793a6a0dd2fe5 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
A drug comorbidity index to predict mortality in men with castration resistant prostate cancer.
por: Giuseppe Fallara, et al.
Publicado: (2021) -
Risk of esophageal and gastric adenocarcinoma in men receiving androgen deprivation therapy for prostate cancer
por: Richard Shore, et al.
Publicado: (2021) -
Mortality following hip fracture in men with prostate cancer.
por: Mieke Van Hemelrijck, et al.
Publicado: (2013) -
Androgen deprivation-induced senescence promotes outgrowth of androgen-refractory prostate cancer cells.
por: Dominick G A Burton, et al.
Publicado: (2013) -
Metabolic changes in patients with prostate cancer with androgen deprivation therapy
por: Maxim N. Peshkov, et al.
Publicado: (2020)